Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
NCT04384458Unknown
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine and CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Proportion of participants in whom there was a positivity for SARS-CoV-2 at Day 52. Status: unknown.
02
Drugs
hydroxychloroquineCHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04384458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384458.